December 10, 2012
Wellesley, Mass. – According to a new technical market research report, PREVENTION AND TREATMENT OF PROSTATE CANCER: TECHNOLOGIES AND GLOBAL MARKETS (PHM113A), from BCC Research (www.bccresearch.com), the global market for the prevention and treatment of prostate cancer was valued at $26.1 billion in 2011 and should reach nearly $29.3 billion in 2012. Total market value is expected to reach $50.3 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 11.4%.
The global prostate cancer market can be broken down into three main segments: diagnosis and screening, surgical and radiation therapy, and drug therapeutics.
The diagnosis and screening segment is expected to total $12.1 billion in 2012 and $17.4 billion in2017, a CAGR of 7.5%
As a segment, surgical and radiation therapy should total $9 billion in 2012 and nearly $14.3 billion in 2017, a CAGR of 9.7%.
Drug therapeutics are expected to reach $8.1 billion in 2012 and nearly $18.6 billion in 2017, a CAGR of 18%.
The hallmark of cancer is uncontrolled growth and the spread of abnormal cells. The disease leads to more than 6 million deaths worldwide each year. The American Cancer Society (ACS) estimates that more than 12 million new cases of cancer are diagnosed worldwide each year. Tremendous progress has been seen in the early diagnoses and treatment methods for cancer during the past few years. Sadly, most of the current methods still in use are conventional therapies such as surgery, radiation, and chemotherapy, all with intense and serious side effects.
Prostate cancer is the most common cancer in males in the United States and other parts of the Western world. The incidence of the disease itself presents a formidable public health problem. More than 240,000 new cases were diagnosed in the United States in 2011, and there are currently approximately 2 million existing cases. It is estimated that nearly 17% of men will receive a prostate cancer diagnosis in their lifetime and that more than $8 billion is spent annually to treat prostate cancer. In 2011, more than 30,000 men in the United States died of the disease.
This report will help its readers:
This report will be valuable to many industry participants, including the following:
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets( PHM113A )
Publish Date: Jan 2013
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.